-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of unknown etiology characterized by progressive narrowing and destruction of the bile ducts due to diffuse inflammation and fibrosis, which eventually leads to cirrhosis and liver failure
The researchers retrospectively analyzed data from the Japanese PSC registry, which included 435 PSC patients
The results of the study showed that of the 435 patients with PSC, 110 were excluded due to insufficient or missing data, and the remaining 325 patients (male, 187 (58%); Mean age of diagnosis, 45.
This study confirmed that UDCA use was significantly associated with improved LT-free survival in patients with PSC, suggesting that UDCA improves long-term prognosis in patients with PSC
Original Source:
Toshihiko Arizumi.